Physician profile
John B Calado
NPI 1972567113
$197,644.99
in general payments reported to CMS, 2019-2025
44 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $1,070 · 2021: $1,362 · 2022: $42K · 2023: $77K · 2024: $28K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Honoraria: $25K · Travel and Lodging: $14K · Food and Beverage: $8,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,400.00 |
| Honoraria | $25,425.00 |
| Travel and Lodging | $13,694.26 |
| Food and Beverage | $8,746.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $160,280.34 | 2019-2025 | Repatha, Repatha, Evenity |
| Axsome Therapeutics, INC. | $29,501.07 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $1,092.94 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $974.30 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $637.39 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Glaxosmithkline, LLC. | $563.90 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Avanir Pharmaceuticals, INC. | $438.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $421.28 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $379.69 | 2019-2025 | Austedo Xr, Ajovy |
| Novo Nordisk INC | $341.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $321.86 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $290.63 | 2022-2025 | Nuzyra, Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.55 | 2019-2022 | |
| Astellas Pharma US INC | $235.59 | 2019-2023 | Veozah |
| Evoke Pharma, INC. | $220.99 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Calado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.